US 11,998,511 B2
Methods, compositions, and devices for supplying dietary fatty acid needs
Alexey L. Margolin, Newton, MA (US); Robert Gallotto, Newton, MA (US); and Bhami Shenoy, South Grafton, MA (US)
Assigned to ALCRESTA THERAPEUTICS, INC., Waltham, MA (US)
Filed by Alcresta Therapeutics, Inc., Newton, MA (US)
Filed on Jun. 29, 2022, as Appl. No. 17/853,168.
Application 17/853,168 is a continuation of application No. 17/211,487, filed on Mar. 24, 2021.
Application 17/211,487 is a continuation of application No. 16/000,327, filed on Jun. 5, 2018, granted, now 10,987,280, issued on Apr. 27, 2021.
Application 16/000,327 is a continuation of application No. 15/684,430, filed on Aug. 23, 2017, granted, now 10,632,047, issued on Apr. 28, 2020.
Application 15/684,430 is a continuation of application No. 15/587,513, filed on May 5, 2017, granted, now 9,775,783, issued on Oct. 3, 2017.
Application 15/587,513 is a continuation of application No. 15/240,596, filed on Aug. 18, 2016, granted, now 9,687,420, issued on Jun. 27, 2017.
Application 15/240,596 is a continuation of application No. 14/378,856, granted, now 9,668,942, issued on Jun. 6, 2017, previously published as PCT/US2013/026063, filed on Feb. 14, 2013.
Claims priority of provisional application 61/719,173, filed on Oct. 26, 2012.
Claims priority of provisional application 61/600,207, filed on Feb. 17, 2012.
Prior Publication US 2022/0331208 A1, Oct. 20, 2022
This patent is subject to a terminal disclaimer.
Int. Cl. C12M 1/00 (2006.01); A23D 7/01 (2006.01); A23D 9/013 (2006.01); A23K 20/158 (2016.01); A23K 50/30 (2016.01); A23L 29/00 (2016.01); A23L 33/00 (2016.01); A23L 33/115 (2016.01); A23L 33/12 (2016.01); A61J 15/00 (2006.01); A61K 9/00 (2006.01); A61K 31/202 (2006.01); A61K 38/46 (2006.01); B65D 1/02 (2006.01); B65D 41/02 (2006.01); B65D 81/32 (2006.01); B65D 85/72 (2006.01)
CPC A61J 15/0092 (2013.01) [A23D 7/011 (2013.01); A23D 7/013 (2013.01); A23D 9/013 (2013.01); A23K 20/158 (2016.05); A23K 50/30 (2016.05); A23L 29/06 (2016.08); A23L 33/115 (2016.08); A23L 33/12 (2016.08); A23L 33/40 (2016.08); A61J 15/0003 (2013.01); A61J 15/0026 (2013.01); A61K 9/0029 (2013.01); A61K 31/202 (2013.01); A61K 38/465 (2013.01); B65D 1/02 (2013.01); B65D 41/02 (2013.01); B65D 81/32 (2013.01); B65D 85/72 (2013.01); C12Y 301/00 (2013.01); A23V 2002/00 (2013.01); C12Y 301/01 (2013.01)] 18 Claims
OG exemplary drawing
 
1. A method of providing a nutritional composition to a subject, the method comprising:
receiving a nutritional composition within an enteral feeding device;
exposing the nutritional composition to lipase immobilized within the enteral feeding device, wherein exposing the nutritional composition to the lipase hydrolyzes triglycerides and/or esters within the nutritional composition to form a hydrolyzed nutritional composition; and
delivering the hydrolyzed nutritional composition from the enteral feeding device to the subject,
wherein the method reduces a length of time the subject is on total parenteral nutrition.
 
11. A method of providing a nutritional composition to a subject, the method comprising:
receiving a nutritional composition within an enteral feeding device;
exposing the nutritional composition to lipase immobilized within the enteral feeding device, wherein exposing the nutritional composition to the lipase hydrolyzes triglycerides and/or esters within the nutritional composition into monoglycerides and free fatty acids to form a hydrolyzed nutritional composition; and
delivering the hydrolyzed nutritional composition from the enteral feeding device and to the subject,
wherein the method reduces gut atrophy in the subject.